CO4940466A1 - Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas - Google Patents
Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadasInfo
- Publication number
- CO4940466A1 CO4940466A1 CO97022872A CO97022872A CO4940466A1 CO 4940466 A1 CO4940466 A1 CO 4940466A1 CO 97022872 A CO97022872 A CO 97022872A CO 97022872 A CO97022872 A CO 97022872A CO 4940466 A1 CO4940466 A1 CO 4940466A1
- Authority
- CO
- Colombia
- Prior art keywords
- salts
- piperazinyl
- dihydro
- ethyl
- benzoisotiazol
- Prior art date
Links
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 title 1
- UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical class O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 abstract 2
- ANMYWYIICWTDRR-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one dihydrate Chemical class O.O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ANMYWYIICWTDRR-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1675796P | 1996-05-07 | 1996-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4940466A1 true CO4940466A1 (es) | 2000-07-24 |
Family
ID=21778804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97022872A CO4940466A1 (es) | 1996-05-07 | 1997-04-29 | Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas |
Country Status (40)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| EP1698338B1 (en) * | 2000-06-02 | 2008-04-09 | Pfizer Products Inc. | S-methyl-dihydro-ziprasidone for the treatment of schizophrenia |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| WO2005016325A2 (en) * | 2003-06-03 | 2005-02-24 | Teva Pharmaceutical Industries Ltd. | CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF |
| US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| MXPA06013163A (es) * | 2004-05-11 | 2007-02-13 | Pfizer Prod Inc | Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b. |
| CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
| CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| CN101106972A (zh) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | 注射用纳米微粒奥氮平制剂 |
| WO2006086787A1 (en) * | 2005-02-11 | 2006-08-17 | Teva Pharmaceutical Industries Ltd. | Process of preparing ziprasidone mesylate |
| US20070032511A1 (en) * | 2005-02-11 | 2007-02-08 | Judith Aronhime | Amorphous ziprasidone mesylate |
| EP1855651A4 (en) * | 2005-03-03 | 2011-06-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES |
| ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
| CA2500667C (en) | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
| US20060270685A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Anhydrous ziprasidone mesylate and a process for its preparation |
| WO2006098834A2 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ziprasidone mesylate |
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| US20080286373A1 (en) * | 2007-05-18 | 2008-11-20 | Palepu Nageswara R | Ziprasidone formulations |
| CA2727573A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
| EP2629775A4 (en) * | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | INJECTABLE FORMULATION WITH DELAYED RELEASE |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5206366A (en) | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5359068A (en) | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| DK0904273T3 (da) | 1996-05-07 | 2003-07-07 | Pfizer | Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist |
-
1997
- 1997-04-01 TW TW086104173A patent/TW491847B/zh not_active IP Right Cessation
- 1997-04-10 PL PL97329884A patent/PL188330B1/pl unknown
- 1997-04-10 SI SI9730676T patent/SI0918772T1/xx unknown
- 1997-04-10 EA EA199800912A patent/EA001190B1/ru not_active IP Right Cessation
- 1997-04-10 KR KR1019980708960A patent/KR100333215B1/ko not_active Expired - Fee Related
- 1997-04-10 PT PT97914520T patent/PT918772E/pt unknown
- 1997-04-10 NZ NZ332218A patent/NZ332218A/en unknown
- 1997-04-10 CN CN97194244A patent/CN1091769C/zh not_active Expired - Fee Related
- 1997-04-10 ES ES97914520T patent/ES2229342T3/es not_active Expired - Lifetime
- 1997-04-10 CA CA002252898A patent/CA2252898C/en not_active Expired - Lifetime
- 1997-04-10 JP JP53967297A patent/JP3494659B2/ja not_active Expired - Lifetime
- 1997-04-10 AU AU21747/97A patent/AU731267B2/en not_active Ceased
- 1997-04-10 US US09/180,455 patent/US6245765B1/en not_active Expired - Lifetime
- 1997-04-10 DK DK97914520T patent/DK0918772T3/da active
- 1997-04-10 UA UA98115905A patent/UA46840C2/uk unknown
- 1997-04-10 CZ CZ19983493A patent/CZ289215B6/cs not_active IP Right Cessation
- 1997-04-10 IL IL12659197A patent/IL126591A/en not_active IP Right Cessation
- 1997-04-10 DE DE69731094T patent/DE69731094T2/de not_active Expired - Lifetime
- 1997-04-10 EP EP97914520A patent/EP0918772B1/en not_active Expired - Lifetime
- 1997-04-10 BR BR9709889A patent/BR9709889A/pt not_active Application Discontinuation
- 1997-04-10 SK SK1508-98A patent/SK282837B6/sk not_active IP Right Cessation
- 1997-04-10 TR TR1998/02240T patent/TR199802240T2/xx unknown
- 1997-04-10 WO PCT/IB1997/000393 patent/WO1997042191A1/en not_active Ceased
- 1997-04-10 AT AT97914520T patent/ATE278689T1/de not_active IP Right Cessation
- 1997-04-29 CO CO97022872A patent/CO4940466A1/es unknown
- 1997-04-29 GT GT199700052A patent/GT199700052A/es unknown
- 1997-04-30 AP APAP/P/1997/000976A patent/AP765A/en active
- 1997-05-04 EG EG37997A patent/EG24076A/xx active
- 1997-05-05 ID IDP971492A patent/ID16867A/id unknown
- 1997-05-05 AR ARP970101856A patent/AR007004A1/es unknown
- 1997-05-06 DZ DZ970069A patent/DZ2222A1/fr active
- 1997-05-06 MA MA24595A patent/MA24171A1/fr unknown
- 1997-05-06 ZA ZA973876A patent/ZA973876B/xx unknown
- 1997-05-06 MY MYPI97001989A patent/MY119997A/en unknown
- 1997-05-06 TN TNTNSN97074A patent/TNSN97074A1/fr unknown
- 1997-05-07 HR HR970236A patent/HRP970236B1/xx not_active IP Right Cessation
-
1998
- 1998-10-20 IS IS4874A patent/IS2080B/is unknown
- 1998-10-30 OA OA9800206A patent/OA10909A/fr unknown
- 1998-11-03 BG BG102892A patent/BG63544B1/bg unknown
- 1998-11-06 NO NO19985194A patent/NO312514B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4940466A1 (es) | Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas | |
| CO4940465A1 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona | |
| PA8518801A1 (es) | Derivados de 2-aminocarbonil-9h-purina | |
| ATE420876T1 (de) | Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| BR9811099A (pt) | Inibidores de urocinase | |
| FI955376A0 (fi) | (3-(4-fenyylipiperatsin-1-yyli)propyyliamino-, tio- ja oksi)pyrdidiini-, -pyrimidiini- ja bentseenijohdannaisia alfa1-adrenoseptoriantagonisteina | |
| NO180445C (no) | 2-(4-hydroksypiperidino)-1-alkanol-derivater som anti-iskemiske midler | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| ES2154318T3 (es) | Agentes antitromboticos. | |
| BR0109483A (pt) | Pró-drogas de derivados de imidazopiridina | |
| HN2001000235A (es) | Derivados puentes de piperazina | |
| ATE219067T1 (de) | Substituierte (2-(1-piperazinyl)ethoxy)methyl- derivate | |
| MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
| BR0114380A (pt) | Derivados-1-aminobutan-3-ol-substituìdos | |
| PT790236E (pt) | Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona | |
| BR9612074A (pt) | Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas | |
| ES2192789T3 (es) | Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios. | |
| DK0888340T3 (da) | 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carboxylsyre-derivater som antagonister for enodthelin | |
| AR027349A1 (es) | Derivados de amidas heterociclicas | |
| MX9205186A (es) | Derivados de 4-[4-[4-(4-hidroxifenil)-1-piperazinil]-fenil]-5-metil-3h-1,2,4-triazo l-3-ona | |
| ECSP972096A (es) | Sales metanosulfanato de 5-[2-[4-[1,2-benzoisotiazol-3- [il] -1 -piperaziniletil]-6-cloro-1,3 2h - indol - 2-ona dihidratas | |
| NO971991L (no) | Heterosyklus-substituerte propensyrederivater som NMDA-antagonister | |
| BR0114459A (pt) | Derivados substituìdos de 5-amino-1-penten-3-ol substituidos | |
| ECSP972089A (es) | Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona |